This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bull of the Day: Veeva Systems (VEEV)
by Benjamin Rains
The AI-boosted medical software stock that's tripled Tech over the last 10 years is on the verge of breaking above a key technical range while trading 15% below its highs.
Veeva Systems Inc. (VEEV) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Veeva (VEEV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Why Veeva Systems (VEEV) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
DOCS Boosts Client Retention via Workflow Integration and AI Tools
by Debanjana Dey
Doximity strengthens client loyalty by embedding AI tools and clinical workflows into its platform for medical professionals.
Best Momentum Stocks to Buy for June 11th
by Zacks Equity Research
SSRM, VEEV and BAESY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 11, 2025.
Is Veeva (VEEV) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Veeva (VEEV) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
New Strong Buy Stocks for June 11th
by Zacks Equity Research
PROSY, EVR, VEEV, BAESY and SSUMY have been added to the Zacks Rank #1 (Strong Buy) List on June 11, 2025.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Do Options Traders Know Something About Veeva Systems Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to VEEV stock based on the movements in the options market lately.
Doximity Declines 4.4% in a Month: How to Play the Stock Now?
by Indrajit Bandyopadhyay
DOCS slips 4.4% in a month despite strong Q4 results, margin gains and raised guidance -- is there a buying opportunity?
Veeva Systems Inc. (VEEV) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Veeva (VEEV). This makes it worthwhile to examine what the stock has in store.
Understanding Veeva (VEEV) Reliance on International Revenue
by Zacks Equity Research
Examine Veeva's (VEEV) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Company News for May 30, 2025
by Zacks Equity Research
Companies in The News Are: A, VEEV, HPQ, BMA
VEEV Stock Up as Q1 Earnings & Revenues Beat Estimates, Margin Rise
by Zacks Equity Research
Veeva Systems' fiscal first-quarter results reflect impressive performance by the Subscription services segment, along with the expansion of gross and operating margins.
Veeva (VEEV) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Veeva (VEEV) give a sense of how the business performed in the quarter ended April 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Veeva Systems (VEEV) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Veeva (VEEV) delivered earnings and revenue surprises of 13.22% and 4.27%, respectively, for the quarter ended April 2025. Do the numbers hold clues to what lies ahead for the stock?
Reasons to Retain Veeva Systems Stock in Your Portfolio for Now
by Zacks Equity Research
VEEV's robust product portfolio and a slew of strategic deals raise optimism about the stock.
2 AI-Driven Tech Stocks to Buy Before they Surge in June
by Benjamin Rains
Diving into some best-in-class, beaten-down tech stocks to buy before everyone else on Wall Street starts searching for deals again.
Brokers Suggest Investing in Veeva (VEEV): Read This Before Placing a Bet
by Zacks Equity Research
The average brokerage recommendation (ABR) for Veeva (VEEV) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Veeva (VEEV) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
by Zacks Equity Research
Evaluate the expected performance of Veeva (VEEV) for the quarter ended April 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Veeva Systems Inc. (VEEV) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Veeva (VEEV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Veeva Systems (VEEV) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
Veeva Systems (VEEV) closed the most recent trading day at $240.78, moving +0.48% from the previous trading session.
P3 Health Partners Inc. (PIII) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
P3 Health Partners (PIII) delivered earnings and revenue surprises of -25.60% and 2.61%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Veeva Systems (VEEV) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
In the most recent trading session, Veeva Systems (VEEV) closed at $240.30, indicating a -0.37% shift from the previous trading day.
Nyxoah SA (NYXH) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Nyxoah (NYXH) delivered earnings and revenue surprises of -28.57% and 29.71%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?